Acta Veterinaria et Zootechnica Sinica ›› 2025, Vol. 56 ›› Issue (3): 1453-1464.doi: 10.11843/j.issn.0366-6964.2025.03.043

• Clinical Veterinary Medicine • Previous Articles     Next Articles

Analysis of the Efficacy of Nodakenin in Canine Atopic Dermatitis

WANG Zijiao(), LIU Chunxiao, LI Guangyu*()   

  1. College of Animal Science and Technology, Qingdao Agricultural University, Qingdao 266109, China
  • Received:2024-04-24 Online:2025-03-23 Published:2025-04-02
  • Contact: LI Guangyu E-mail:wzjdgg1022@163.com;tcslgy@126.com

Abstract:

Canine atopic dermatitis (CAD) is a complex inflammatory skin disease associated with alterations in the skin microbiota, immunity and skin barrier. Nodakenin is a coumarin glycoside with anti-inflammatory, antimicrobial and antioxidant properties. The aim of this study was to investigate the intervention effect of Nodakenin on 2, 4-dinitrotoluene (DNCB)-induced canine atopic dermatitis as well as the effect of skin microbiota. DNCB-induced canine atopic dermatitis was first established, and nodakenin was administered for 14 days as a topical application treatment. The effect of nodakenin treatment was assessed by body weight indexes, routine blood tests, serum biochemical tests, serum immunoglobulin E (IgE) levels, the degree of skin lesions and itching, and the results of 16S rRNA sequencing of skin microbiota. Compared with the DNCB group, the nodakenin group showed a significant increase in body weight, a significant increase in the total number of leukocytes and the percentage of neutrophils in the routine blood indexes (P < 0.05), while there was no significant difference in the serum biochemical related indexes (P>0.05), a significant decrease in the serum IgE content (P < 0.05), and a significant improvement in the degree of skin lesions and itching (P < 0.01). There were significant differences in both alpha diversity and beta diversity in the skin microbiota (P < 0.05), and at the phylum level, the relative abundance of the thick-walled phylum Firmicutes was significantly restored after nodakenin treatment (P < 0.01). At the genus level, nodakenin treatment significantly increased the relative abundance of Romboutsia, Clostridium_sensu_stricto_1, and Terrisporobacter (P < 0.01 and P < 0.05, respectively) and significantly decreased the relative abundance of Moraxella and Staphylococcus spp. relative abundance (P < 0.05). The application of nodakenin can effectively reduce the degree of skin lesions, alleviate itchy skin, reduce serum IgE levels, and regulate the imbalance of skin microbiota, thus improving the symptoms of canine atopic dermatitis and providing a new idea for drug development for CAD.

Key words: nodakenin, 2, 4-dinitrochlorobenzene(DNCB), canine atopic dermatitis, skin microbiota

CLC Number: